Compare FSBC & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBC | CRMD |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.2M | 876.7M |
| IPO Year | 2021 | 2010 |
| Metric | FSBC | CRMD |
|---|---|---|
| Price | $37.06 | $11.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $37.83 | $17.43 |
| AVG Volume (30 Days) | 57.1K | ★ 2.9M |
| Earning Date | 01-26-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | ★ 19.76 | N/A |
| EPS | ★ 2.70 | 2.25 |
| Revenue | $141,930,000.00 | ★ $214,303,672.00 |
| Revenue This Year | $34.35 | $627.89 |
| Revenue Next Year | $17.79 | $40.95 |
| P/E Ratio | $13.72 | ★ $5.10 |
| Revenue Growth | 25.41 | ★ 1647.67 |
| 52 Week Low | $22.22 | $5.60 |
| 52 Week High | $37.74 | $17.43 |
| Indicator | FSBC | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 66.10 | 61.66 |
| Support Level | $34.49 | $10.90 |
| Resistance Level | $35.48 | $12.10 |
| Average True Range (ATR) | 1.10 | 0.50 |
| MACD | 0.27 | 0.24 |
| Stochastic Oscillator | 98.56 | 83.07 |
Five Star Bancorp is a bank holding company through its subsidiary it operates in California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment; Banking.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.